Pfizer's (PFE) and Bristol-Myers Squibb's (BMY) Eliquis blood thinner cut the risk of clots in...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Pfizer's (PFE) and Bristol-Myers Squibb's (BMY) Eliquis blood thinner cut the risk of clots in veins and lungs, and death, by 81% compared with a placebo in major year-long trial. Bleeding was also low. BMY could rack up sales of $4.18B by 2018 if Eliquis is approved - the drug would compete with warfarin, Xarelto from Bayer and J&J (JNJ), and Pradaxa from Boehringer Ingelheim. (PR)